Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evgen Pharma ( (GB:TCF) ) has provided an update.
TheraCryf has announced advancements in its second preclinical program, a dopamine modulator (DAT) targeting mental and cognitive fatigue, which has demonstrated promising results in alleviating fatigue without the side effects of conventional stimulants. With central nervous system-related fatigue linked to various severe conditions and no approved treatments currently available, this breakthrough positions TheraCryf to address a growing market expected to double in size to $2.3 billion by 2033, bringing significant potential value to the company and its stakeholders.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical-stage drug development company specializing in treatments for brain disorders, including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company operates from its headquarters in Alderley Park, Cheshire, and collaborates with leading universities, hospitals, and pharmaceutical firms to advance its pipeline. It is listed on AIM in London under the ticker symbol TCF.
Average Trading Volume: 2,528,411
Technical Sentiment Signal: Sell
Current Market Cap: £4.51M
For an in-depth examination of TCF stock, go to TipRanks’ Overview page.